Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Fermion OK’d to Start China Trials of Novel JAK inhibitor for Autoimmune Diseases

publication date: Feb 6, 2024

Guangzhou Fermion Technology was approved to start clinical trials of FZ007-119, a third-gen JAK inhibitor targeting TYK2 JH2 for autoimmune diseases, including moderate to severe plaque psoriasis. The candidate, which is Fermion’s third molecule to begin clinical trials, was developed using Fermion's proprietary Drug Studio AI drug development platform. Fermion says FZ007-119 showed much higher selectivity than older JAK inhibitors, which could offer better safety than existing drugs. An AI and data-driven novel drug development company, Fermion develops potential BIC/FIC candidates for central nervous system and autoimmune indications. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital